Literature DB >> 25712050

Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3β.

Xiangmei Chen1, Ling Zhang2, Sujun Zheng3, Ting Zhang1, Meng Li1, Xiaolei Zhang1, Zhenzhen Zeng1, Malcolm A McCrae4, Jingmin Zhao5, Hui Zhuang1, Fengmin Lu6.   

Abstract

The Hepatitis B virus X protein (HBx) contributes centrally to the pathogenesis of hepatocellular carcinoma (HCC). It has been suggested that the transcriptional activation of cyclin D1 by HBx is implicated in the development of HCC. However, numerous studies have shown that overexpression of cyclin D1 alone is not sufficient to drive oncogenic transformation. Herein, we investigated whether HBx can stabilize cyclin D1 and induce cyclin D1 protein nuclear accumulation, and thereby accelerate hepatocarcinogenesis. The effects of HBx on cyclin D1 stabilization were assessed in cell-based transfection, Western blot, immunoprecipitation, immunocytofluorescence staining, and flow-cytometric assays. The results demonstrated that ectopic expression of HBx in HCC cells could extend the half-life of cyclin D1 protein from 40-60 minutes to 80-110 minutes. HBx stabilized cyclin D1 primarily in the S phase of the cell cycle, in a manner dependent on the inactivation of GSK-3β, which was mediated by ERK activation. HBx also prompted the nuclear accumulation of cyclin D1, and cotransfection of the constitutively active mutant of GSK-3β along with HBx could reverse the nuclear accumulation and subsequent cell proliferation induced by HBx. Further, a positive correlation between HBx and nuclear cyclin D1 level was established in HCC specimens detected by an immunohistochemical assay. Taken together, our results indicated that HBx could stabilize and increase cyclin D1 nuclear accumulation through ERK-mediated inactivation of GSK-3β. This HBx-induced cyclin D1 upregulation might play an important role in HCC development and progression. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25712050     DOI: 10.1158/1940-6207.CAPR-14-0384

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  10 in total

1.  Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.

Authors:  Zhenzhen Zeng; Jing Tu; Jin Cheng; Mingjie Yao; Yali Wu; Xiangbo Huang; Xiaomeng Xie; Xiaolei Zhang; Fengmin Lu; Xiangmei Chen
Journal:  Tumour Biol       Date:  2015-04-08

2.  Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Yuanwei Zang; Xiang Zhang; Lei Yan; Gangli Gu; Dawei Li; Yongzhen Zhang; Liang Fang; Shanshan Fu; Juchao Ren; Zhonghua Xu
Journal:  J Cancer       Date:  2017-09-02       Impact factor: 4.207

3.  Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection.

Authors:  Jun Hou; Willem P Brouwer; Kim Kreefft; Lucio Gama; Sarah L Price; Harry L A Janssen; Pim J French; Thomas Vanwolleghem; Andre Boonstra
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

4.  Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression.

Authors:  Wen-Shu Chen; Liang-Chih Liu; Chia-Jui Yen; Yun-Ju Chen; Jhen-Yu Chen; Chien-Yi Ho; Shu-Hui Liu; Ching-Chow Chen; Wei-Chien Huang
Journal:  Oncotarget       Date:  2016-08-30

5.  The Effects of Qinghao-Kushen and Its Active Compounds on the Biological Characteristics of Liver Cancer Cells.

Authors:  Jingmin Ji; Zhiqin Zhang; Qing Peng; Liyuan Hao; Yinglin Guo; Yu Xue; Yiwei Liu; Caige Li; Xinli Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-10       Impact factor: 2.650

6.  Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xu Cao; Hening Chen; Zhiguo Li; Xiaoke Li; Xianzhao Yang; Qiushuo Jin; Yijun Liang; Jiaxin Zhang; Meiyue Zhou; Ningyi Zhang; Guang Chen; Hongbo Du; Xiaobin Zao; Yong'an Ye
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

7.  Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice.

Authors:  Gayathri Balandaram; Lance R Kramer; Boo-Hyon Kang; Iain A Murray; Gary H Perdew; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2016-07-15       Impact factor: 4.571

8.  Chemopreventive effect of resveratrol and apocynin on pancreatic carcinogenesis via modulation of nuclear phosphorylated GSK3β and ERK1/2.

Authors:  Akihisa Kato; Aya Naiki-Ito; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Katsuyuki Miyabe; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Michihiro Yoshida; Shuichiro Umemura; Yasuki Hori; Toshio Mori; Masahiro Tsutsumi; Toshiya Kuno; Shugo Suzuki; Hiroyuki Kato; Hirotaka Ohara; Takashi Joh; Satoru Takahashi
Journal:  Oncotarget       Date:  2015-12-15

9.  Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer.

Authors:  Zhen-Qiang Wang; Qiang Cai; Lei Hu; Chang-Yu He; Jian-Fang Li; Zhi-Wei Quan; Bing-Ya Liu; Chen Li; Zheng-Gang Zhu
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

Review 10.  The regulation of β-catenin activity and function in cancer: therapeutic opportunities.

Authors:  Shuang Shang; Fang Hua; Zhuo-Wei Hu
Journal:  Oncotarget       Date:  2017-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.